Galectin Therapeutics director Kevin Freeman acquires $8,134 in inventory

Kevin D. Freeman, a director at Galectin Therapeutics Inc. (NASDAQ:GALT), lately bought 10,000 shares of the corporate’s widespread inventory. The transaction, which befell on December 24, 2024, was executed at a value of $0.8134 per share, leading to a complete buy worth of $8,134. The acquisition comes because the inventory trades close to its 52-week low of $0.73, having declined almost 58% prior to now week alone. In response to InvestingPro evaluation, the $53 million market cap firm seems undervalued at present ranges.

Following this acquisition, Freeman now straight owns 44,769 shares of Galectin Therapeutics. Moreover, he holds 80,000 shares not directly via Freeman International Holdings LLC, a restricted legal responsibility firm he controls, and 18,063 shares in a person retirement account (IRA).

Freeman has disclaimed helpful possession of the securities held by Freeman International Holdings LLC, besides to the extent of his pecuniary curiosity.

In different latest information, Galectin Therapeutics disclosed outcomes from its NAVIGATE medical trial, suggesting that belapectin may lower the formation of esophageal varices in sufferers with Metabolic Dysfunction-Related Steatohepatitis (MASH) cirrhosis and portal hypertension. The trial concerned over 130 websites worldwide and included 355 sufferers who have been administered both belapectin or a placebo for 18 months. Within the per-protocol inhabitants, belapectin at 2mg/kg of lean physique mass demonstrated a 48.9% discount within the incidence of varices in comparison with the placebo, attaining statistical significance. Nevertheless, the drug didn’t meet the first endpoint of statistical significance within the broader intent-to-treat inhabitants.

Non-invasive measures supported these outcomes, with liver stiffness assessments revealing a 50% decrease variety of topics with worsening stiffness amongst these handled with belapectin. The protection profile was additionally favorable, with comparable charges of antagonistic occasions and critical antagonistic occasions throughout all cohorts. The corporate stays optimistic about belapectin’s potential and is actively looking for pharmaceutical partnerships to advance its growth.

Dr. Khurram Jamil, Chief Medical (TASE:PMCN) Officer at Galectin Therapeutics, anticipates additional updates from ongoing analyses, together with extra biomarker information anticipated in early 2025. Regardless of the corporate’s monetary challenges, as indicated by a weak general well being rating and destructive earnings per share of -$0.73, analysts keep an $11 value goal, suggesting important upside potential.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.